Literature DB >> 11823982

Central nervous system aspergillosis: a 20-year retrospective series.

B K Kleinschmidt-DeMasters1.   

Abstract

Over the past 20 years at my institution, 71 patients with invasive necrotizing aspergillosis have been encountered; 42 have shown central nervous system (CNS) involvement by autopsy (40) or surgical biopsy (2). Most non-CNS aspergillosis patients had invasive disease confined to the lung, and only 2 with dissemination to 3 or more organs did not have spread to the CNS. In addition to the expected post-transplantation and hematologic malignancy cases, other risk groups identified included those with chronic asthma and steroid use, acquired immunodeficiency syndrome, thermal burn, hepatic failure, and postoperative infection. Unusual cases manifested with basilar meningitis, myelitis, proptosis caused by sino-orbital disease, or epidural and subdural Aspergillus abscesses. The extent of gross neuropathologic disease ranged from subtle abscesses to massive hemorrhagic necrosis causing herniation and death. In addition to the expected hemorrhagic necrosis, extensive hemorrhage, focal purulent meningitis, and subtle bland infarctions were also seen. Distinctive microscopic findings encountered included 1 case with numerous meningeal granulomas and multinucleated giant cells and 4 cases showing the Splendore-Hoeppli phenomenon. During the same period, single cases of cerebritis caused by morphologically similar fungi (Pseudoallescheria boydii [Scedosporium apiospermum], Scedosporium inflatum, Chaetomium sp) were identified and were indistinguishable from CNS aspergillosis clinically and pathologically. Copyright 2002 by W.B. Saunders Company

Entities:  

Mesh:

Year:  2002        PMID: 11823982     DOI: 10.1053/hupa.2002.30186

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  34 in total

1.  Evaluation and treatment of chronic meningitis.

Authors:  Kelly J Baldwin; Joseph R Zunt
Journal:  Neurohospitalist       Date:  2014-10

2.  Central Nervous System Aspergillosis causing Spinal Cord Compression.

Authors:  Faraz Ahmed; Riaz Ahmed
Journal:  Oman Med J       Date:  2010-07

3.  Aspergillosis of biliary tract after liver transplantation: a case report.

Authors:  Chen Yuchong; Zhu Dingheng; Yuan Zhizhong; Yu Hongyu; He Jing; Chen Jianghan
Journal:  Mycopathologia       Date:  2010-03-24       Impact factor: 2.574

Review 4.  Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature.

Authors:  Joel W Alderson; Thomas G Van Dinter; Michael J Opatowsky; Elizabeth C Burton
Journal:  MedGenMed       Date:  2005-09-21

5.  Multiple intracranial fungal abscesses in an immunocompetent infant treated surgically.

Authors:  Ashutosh Khandelwal; Noufal Basheer; Ashok K Mahapatra
Journal:  J Pediatr Neurosci       Date:  2014-05

Review 6.  Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection.

Authors:  I Mirkov; S Stosic-Grujicic; M Kataranovski
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

7.  Unusual case of cerebral aspergillosis with clinical and imaging findings mimicking lymphoma.

Authors:  C Sidani; M E Freiser; G Saigal; E Sklar
Journal:  Neuroradiol J       Date:  2013-07-16

Review 8.  Fungal infections of the CNS: treatment strategies for the immunocompromised patient.

Authors:  Katharine E Black; Lindsey R Baden
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  The radiological spectrum of invasive aspergillosis in children: a 10-year review.

Authors:  Karen E Thomas; Catherine M Owens; Paul A Veys; Vas Novelli; Vera Costoli
Journal:  Pediatr Radiol       Date:  2003-05-09

10.  Central nervous system Aspergillus infection after epidural analgesia: diagnosis, therapeutic challenges, and literature review.

Authors:  Jonathan R Genzen; Barton Kenney
Journal:  Diagn Microbiol Infect Dis       Date:  2009-08-29       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.